LAMTOR3P1: A Drug Target / Disease Biomarker (G100130119)

Target Name: LAMTOR3P1

NCBI ID: G100130119

LAMTOR3P1

Other Name(s): late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 pseudogene 1 | Late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 pseudogene 1

LAMTOR3P1: A Drug Target / Disease Biomarker

LAMTOR3P1, also known as LAMTOR3P1-T2, is a protein that is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. It is a key regulator of the muscle-brain plasticity, which is the ability of the brain to adapt and learn new things.

Recent studies have suggested that LAMTOR3P1 may have potential as a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

One of the reasons for the interest in LAMTOR3P1 is its role in the regulation of muscle-brain plasticity. Studies have shown that LAMTOR3P1 is involved in the formation and maintenance of synapses, which are the connections between neurons in the brain. When we learn new things or perform a new exercise, our muscles require more synapses to function properly. LAMTOR3P1 plays a key role in this process by ensuring that the number of new synapses that form is consistent with the level of training or learning that is occurring.

Another potential mechanism by which LAMTOR3P1 may be involved in neurological disorders is its role in the regulation of neurotransmitter release. Neurotransmitters are chemical messengers that are used by the brain to communicate with other neurons and cells. Studies have shown that LAMTOR3P1 is involved in the release of various neurotransmitters, including dopamine, serotonin, and endocannabinoids. The exact role of LAMTOR3P1 in neurotransmitter release is not well understood, but it is possible that it may be involved in the treatment of certain neurological disorders.

In addition to its potential role in the regulation of muscle-brain plasticity and neurotransmitter release, LAMTOR3P1 may also be involved in the development and progression of certain neurological disorders. Studies have shown that LAMTOR3P1 is expressed in the brains of individuals with Alzheimer's disease, and that it is involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. Additionally, LAMTOR3P1 has also been shown to be involved in the development of Parkinson's disease, and may play a role in the regulation of dopamine levels in this disorder.

Given the potential involvement of LAMTOR3P1 in a variety of neurological and psychiatric disorders, it is an attractive target for drug development. Studies are currently being conducted to determine the exact role of LAMTOR3P1 in these disorders, as well as to identify potential small molecules that can inhibit its activity. If LAMTOR3P1 turns out to be a useful drug target or biomarker, it has the potential to revolutionize our understanding of these disorders and lead to new treatments.

Protein Name: Late Endosomal/lysosomal Adaptor, MAPK And MTOR Activator 3 Pseudogene 1

The "LAMTOR3P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LAMTOR3P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets